证券代码：688755 证券简称：汉邦科技 公告编号：2026-001 江苏汉邦科技股份有限公司 关于注销募集资金现金管理产品专用结算账户的公告 二、本次募集资金现金管理专用结算账户的注销情况 截至本公告披露日，公司在上述募集资金现金管理产品专用结算账户内的理 财产品已全部到期，现金管理专用结算账户内资金已全部赎回且在此账户无下一 步购买计划，根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》等相关规定，公司于近日办理完毕上述募集资金现金管理专用结算账户的注 销手续。具体账户信息如下： | 序号 | 账户名称 | 开户机构 | 资金账号 | 账户状态 | | --- | --- | --- | --- | --- | | 1 | 江苏汉邦科技股 | 兴业银行股份有限公司 | 402310100200343110 | 本次注销 | | | 份有限公司 | 淮安分行 | | | | 2 | 江苏汉邦科技股 | 中国建设银行股份有限公 | 32001725336049505688*219 | 本次注销 | | | 份有限公 ...

Core Viewpoint - Hanbang Technology's industrial preparation liquid chromatography systems and related purification equipment are widely applicable in the biopharmaceutical sector, including the separation and purification of insulin, antibodies, vaccines, and antibiotics [1] Group 1 - The company closely monitors changes in downstream market demand and actively seizes market opportunities [1] - Specific order situations can be found in the company's disclosed periodic reports [1]

Group 1 - The article highlights the behavior of margin traders, indicating that investors are looking for investment opportunities through their activities [1] - On December 30, a total of 3,757 stocks received margin buying funds, with the top three stocks being Sanhua Intelligent Controls at 2.296 billion, Zhongji Xuchuang at 2.293 billion, and Xinyi Sheng at 1.910 billion [1] - Among the stocks with significant margin buying, 10 stocks had a margin buying amount that exceeded 30% of their total trading volume [1] Group 2 - The top stocks by margin buying amount and their respective trading volumes and percentages are detailed, with notable mentions including Qingtang City at 24.35 million and Daya Shengxiang at 12.86 million [2] - The data shows that the margin buying percentage for several stocks is high, with Qingtang City at 43.09%, Daya Shengxiang at 40.80%, and Guangming Meat Industry at 35.66% [1][2] - The article provides a comprehensive table listing various stocks, their margin buying amounts, total trading amounts, margin buying percentages, and daily price changes [1][2]

Core Insights - The article discusses the successful hosting of the "Qihang·2025 Financial Annual Conference" in Beijing, where Tang Yefeng, Vice President and Secretary of the Board of Jiangsu Hanbang Technology Co., Ltd. (Hanbang Technology), shared insights on the company's post-IPO development, core technology industrialization, domestic substitution progress in chromatography equipment, and the "14th Five-Year Plan" strategic layout [1][2]. Company Overview - Hanbang Technology, established in 1998, focuses on chromatography technology, integrating R&D, production, and sales, primarily serving the pharmaceutical and life sciences sectors with professional separation and purification equipment, consumables, and related solutions [3]. - The company has a leading position in the domestic chromatography separation and purification equipment market, holding a 39.2% market share in production-level small molecule separation and purification equipment, ranking first, and an 8.8% market share in large molecule equipment, ranking third [3]. IPO Impact - The IPO completed in May 2025 is viewed as a significant milestone, acting as an "accelerator" for high-quality development across three dimensions: enhancing capital strength, improving governance structure, and increasing resource integration capabilities [4]. - Funds raised from the IPO are directed towards projects such as the annual production of 1,000 liquid chromatography equipment and the establishment of a chromatography separation equipment R&D center, which will support capacity expansion and sales growth [4]. Value Communication - The role of the Secretary of the Board is crucial in conveying value for technology-intensive newly listed companies, focusing on translating complex technical systems into understandable market value propositions and establishing communication channels with investors [5]. Technological Advancements - Hanbang Technology has developed a unique technology system characterized by "one core, two nuclei, and multiple uses," focusing on core chromatography column technology and expanding into various product and service applications [6]. - The company is committed to continuous R&D investment and has established platforms such as provincial engineering research centers to tackle key technologies and enhance industrialization [6]. Domestic Substitution Progress - The domestic substitution of chromatography separation and purification equipment is at a critical stage, with Hanbang Technology leading in small molecule production equipment and accelerating its market share in large molecule equipment [7]. - The company has established three differentiated advantages: competitive product performance, localized service capabilities, and a comprehensive product line offering customized solutions [7]. Strategic Focus for the 14th Five-Year Plan - The "14th Five-Year Plan" emphasizes high-quality development and technological self-reliance, presenting significant opportunities for the biopharmaceutical upstream equipment industry [8]. - Hanbang Technology is focusing on three key areas: large molecule biopharmaceuticals, nucleic acid and peptide drugs, and the domestic substitution of chromatography fillers, aiming to break the monopoly of foreign brands [8].

Core Insights - The "Qihang·2025 Financial Summit" was successfully held in Beijing, focusing on "New Starting Point, New Momentum, New Journey," gathering leaders and guests from various sectors including regulatory bodies, financial institutions, and media [1] - The 14th "Golden Wisdom Award" results were announced, with Hanbang Technology winning the "Excellence Award in the Pharmaceutical and Biological Industry" [1][4] Group 1: Award Significance - The "Golden Wisdom Award" aims to establish benchmarks for high-quality development, guiding listed companies to focus on their core businesses, innovate continuously, and fulfill social responsibilities [4] - The award evaluation covered over 8,000 companies across A-shares, Hong Kong stocks, and Chinese concept stocks, ultimately recognizing nearly 200 award-winning enterprises [4] Group 2: Hanbang Technology's Achievements - Hanbang Technology is recognized for its innovation and comprehensive strength in the pharmaceutical and biological industry, focusing on high-quality development and leading industry trends [4][5] - The company has developed a full product matrix from bioreactors to purification equipment, breaking foreign technology monopolies and filling gaps in the domestic high-end biopharmaceutical equipment sector [5] Group 3: Innovation and R&D - Hanbang Technology emphasizes "innovation-driven, clinical-oriented, and people-centered" development, continuously increasing R&D investment and forming a virtuous cycle of "R&D - transformation - industrialization" [5][6] - The company’s products are widely used in the development and large-scale production of biopharmaceuticals, helping pharmaceutical companies shorten R&D cycles and reduce production costs [5] Group 4: Future Outlook - Hanbang Technology plans to continue its commitment to innovation, increasing investment in core technology R&D, and expanding into emerging fields such as cell and gene therapy [6] - The company aims to empower innovative drug R&D and clinical transformation through collaborative efforts across the industry chain, contributing to the high-quality development of the biopharmaceutical industry under the "14th Five-Year Plan" [6]

Group 1 - The core viewpoint of the news is that Hanbang Technology's stock performance and financial metrics indicate a mixed outlook, with slight revenue growth but a decline in net profit [1][2]. - On December 22, Hanbang Technology's stock fell by 0.05%, with a trading volume of 14.69 million yuan. The financing data shows a net buying of 1.29 million yuan for the day [1]. - As of December 22, the total balance of margin trading for Hanbang Technology was 74.60 million yuan, with the financing balance accounting for 10.64% of the circulating market value [1]. Group 2 - As of September 30, the number of shareholders for Hanbang Technology was 8,687, a decrease of 7.31% from the previous period, while the average circulating shares per person increased by 7.89% [2]. - For the period from January to September 2025, Hanbang Technology achieved operating revenue of 506 million yuan, representing a year-on-year growth of 4.61%. However, the net profit attributable to the parent company decreased by 17.27% to 37.02 million yuan [2]. - Since its A-share listing, Hanbang Technology has distributed a total of 8.80 million yuan in dividends [2].

Group 1 - The core viewpoint of the news is that Hanbang Technology experienced a slight decline in stock price and a net financing outflow on December 18, 2023, with a total trading volume of 12.75 million yuan [1] - On December 18, Hanbang Technology had a financing buy amount of 1.29 million yuan and a financing repayment of 3.53 million yuan, resulting in a net financing buy of -2.24 million yuan [1] - As of December 18, the total balance of margin trading for Hanbang Technology was 73.94 million yuan, accounting for 10.67% of its circulating market value [1] Group 2 - As of September 30, 2023, Hanbang Technology had 8,687 shareholders, a decrease of 7.31% from the previous period, while the average circulating shares per person increased by 7.89% [2] - For the period from January to September 2023, Hanbang Technology achieved an operating income of 506 million yuan, representing a year-on-year growth of 4.61%, while the net profit attributable to the parent company was 37.02 million yuan, a decrease of 17.27% year-on-year [2] - Since its A-share listing, Hanbang Technology has distributed a total of 8.8 million yuan in dividends [3]

Group 1 - The core viewpoint of the articles highlights the fundraising activities of companies listed on the STAR Market, with a total of 17 companies raising 35.089 billion yuan this year, averaging 2.064 billion yuan per company [1][2] - Among the companies, Moer Technology raised the most at 8 billion yuan, primarily for cash management and the development of AI training chips and graphics chips [1] - Other notable fundraisers include Xian Yicai with 4.636 billion yuan for its silicon industry base project, and Muxi Co., Ltd. with 4.197 billion yuan [1] Group 2 - The average initial offering price for STAR Market stocks this year is 36.56 yuan, with four companies priced above 50 yuan, and two exceeding 100 yuan, the highest being Moer Technology at 114.28 yuan [2] - The issued price-earnings ratio ranges from 6.14 to 519.12, with an average of 83.91 and a median of 42.64, where C Bai Ao has the highest ratio at 519.12 [2] - Geographically, the majority of the issued companies are concentrated in Beijing, Hubei, and Guangdong, with fundraising amounts led by Beijing at 14.692 billion yuan [2]

Core Points - Hanbang Technology's stock price decreased by 1.76% on November 17, with a trading volume of 42.3962 million yuan [1] - The company recorded a net financing purchase of 1.1831 million yuan on the same day, with a total financing balance of 80.224 million yuan, accounting for 10.58% of its market capitalization [1] - As of September 30, the company achieved a revenue of 506 million yuan, representing a year-on-year growth of 4.61%, while the net profit attributable to shareholders decreased by 17.27% to 37.0172 million yuan [2] Financing and Trading Data - On November 17, Hanbang Technology had a financing buy amount of 2.7984 million yuan and a financing repayment of 1.6154 million yuan [1] - The company had no short selling activity on November 17, with a short selling balance of 0 [1] - The total number of shareholders as of September 30 was 8,687, a decrease of 7.31% from the previous period [2] Business Overview - Hanbang Technology, established on October 28, 1998, specializes in providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1] - The revenue composition of the company includes 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1] - The company has distributed a total of 8.8 million yuan in dividends since its A-share listing [3]

Group 1 - The company, Hanbang Technology (688755.SH), focuses on small molecule liquid chromatography and large molecule chromatography equipment primarily used in the biopharmaceutical field, including the development and production of antibodies, recombinant proteins, vaccines, insulin, and peptides [1] - The company emphasizes technology research and development as its core, aiming to provide customers with integrated solutions of "equipment + consumables + process development" to support key technological breakthroughs in the biomanufacturing sector [1] Group 2 - An investor inquired about the company's separation and purification equipment used in biomanufacturing and whether its current R&D projects involve key technological breakthroughs in this field, as highlighted in the 14th Five-Year Plan [3]